{{Rsnum
|rsid=7378340
|Gene=SLC2A9
|Chromosome=4
|position=9953574
|Orientation=plus
|GMAF=0.3994
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SLC2A9
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 36.3 | 44.2 | 19.5
| HCB | 81.0 | 19.0 | 0.0
| JPT | 85.8 | 14.2 | 0.0
| YRI | 6.1 | 39.5 | 54.4
| ASW | 7.0 | 57.9 | 35.1
| CHB | 81.0 | 19.0 | 0.0
| CHD | 73.4 | 22.9 | 3.7
| GIH | 64.4 | 30.7 | 5.0
| LWK | 10.9 | 41.8 | 47.3
| MEX | 31.0 | 50.0 | 19.0
| MKK | 16.0 | 50.6 | 33.3
| TSI | 37.3 | 48.0 | 14.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs7378340
|Name_s=
|Gene_s=SLC2A9
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109502
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs7378340
|overall_frequency_n=54
|overall_frequency_d=128
|overall_frequency=0.421875
|n_genomes=37
|n_genomes_annotated=0
|n_haplomes=51
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}